Tech Company Financing Transactions
Entasis Therapeutics Funding Round
Entasis Therapeutics, operating out of Waltham, raised $31.9 million from Clarus, Eventide Asset Management and Frazier Healthcare Partners.
Transaction Overview
Company Name
Announced On
9/6/2017
Transaction Type
Venture Equity
Amount
$31,900,000
Round
Series B
Investors
Clarus (Lead Investor) (Nicholas Galakatos)
Frazier Healthcare Partners (James Topper)
Proceeds Purpose
This additional financing will enable us to continue advancing our portfolio of innovative anti-infective programs into mid and late-stage clinical development, with an immediate focus on drug-resistant, Gram-negative bacterial infections that currently have high mortality rates and significant unmet medical needs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Entasis Therapeutics (Nasdaq: ETTX) is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Manos Perros
Chief Medical Officer
David Altarac
Chief Scientific Officer
Ruben Tommasi
VP - Bus. Development
Michael Gutch
VP - Bus. Development
Eric Kimble
VP - Bus. Development
John Mueller
Browse more venture capital transactions:
Prev: 9/6/2017: Joi Scientific venture capital transaction
Next: 9/6/2017: Allbirds venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs